Nexgel Inc

Nexgel Inc(NXGL)股票分析

$3.720

-0.359 (-9.65%)收盘时

Loading chart…
最高
3.800
开盘
3.800
成交量加权均价
3.71
成交量
13.83K
市值
13.55M
最低
3.600
成交额
51.27K
企业价值/息税折旧摊销前利润(TTM)
-0.61

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.

AI 分析 of Nexgel Inc (NXGL)

卖出

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

估值指标

Nexgel Inc(NXGL)当前预期市盈率为 1.38,5 年平均预期市盈率为 -12.03。

预期市盈率

合理
5 年均值 P/E
-12.03
当前P/E
1.38
高估
8.24
低估
-32.31

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
20.87
当前EV/EBITDA
-0.61
高估
104.38
低估
-62.63

预期市销率

低估
5 年均值 P/S
2.06
当前P/S
0.08
高估
3.55
低估
0.56

Alphio AI 对 NXGL 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%NXGL

$6.00

情景价格

基

基准

基准 · 50%NXGL

$5.53

情景价格

悲

悲观

悲观 · 25%NXGL

$5.37

情景价格

事件时间线

2026-10-09 (ET)

20:00:00

Nexgel Inc Trading Halted, News Pending

2026-08-20 (ET)

16:30:00

Company Establishes Special Committee for Strategic Review

16:30:00

NexGel Appoints Brian Kieser as Interim CEO

13:00:00

Selling Stockholders Plan to Sell 15.25M Shares of Common Stock

2026-05-19 (ET)

09:20:00

NexGel Reports Clinical Study Data Showing 37.2% Reduction in Hair Density

资讯

NXGL 常见问题 —— 由 Alphio AI 解答

NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Nexgel Inc is not a good buy right now due to significant financial instability and negative trends. The current price is $3.72, and the company has a troubling year-to-date change of -89.72%, indicating severe underperformance. Additionally, the RSI is at 37.396, suggesting the stock is nearing oversold territory, but this does not guarantee a rebound. The main risk is the upcoming earnings report on November 10, 2026, where the EPS estimate is -4.80, which could further pressure the stock if results disappoint.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易